



A NOVEL, HOST-DIRECTED, SMALL MOLECULE INHIBITOR OF HCV DISPLAYS SUSTAINED PHARMACOLOGICAL INHIBITION OF LIVER FATTY ACID SYNTHASE

Marc Evanchik, Yuko Kosaka, Samnang Tep, Mohanram Sivaraja, Shirley Feng, Haiying Cai, Lily Hu, Russell Johnson, Julie Lai, Hanbiao Yang, Cristiana Zaharia, George Kemble, Johan Oslob, Robert McDowell

3-V Biosciences, Inc., 1050 Hamilton Court, Menlo Park, CA


Abstract

BACKGROUND: Optimized new therapies for HCV are needed that have pan genotypic activity and a high barrier to viral resistance. To meet these challenges, 3-V Biosciences has developed a small molecule inhibitor of HCV that targets the host's fatty acid synthase (FASN) enzyme (Abstract 88). HCV infection increases the expression of FASN, the host enzyme responsible for the production of palmitate, and down regulation of FASN inhibits critical viral processes including entry into cells, RNA replication, and particle assembly. FASN inhibitors are expected to have pan-genotypic activity and pose a high barrier to viral resistance due to interference with multiple stages of the HCV lifecycle.

OBJECTIVE: The objective of this study is to characterize the pharmaceutical properties of a novel, small molecule inhibitor of FASN as a treatment for chronic HCV infection.

RESULTS: 3-V Bioscience's FASN small molecule inhibits the human FASN enzyme in biochemical and cell based assays with an IC₅₀ of 0.049 μM and 0.025 μM, respectively. Activity against the HCV Gt1b replicon parallels FASN inhibition with an EC₅₀ of 0.060 μM and no observed cytotoxicity. A 10 mpk oral dose of this compound is rapidly absorbed and highly bioavailable (~60%) in rats and dogs with an apparent half-life of 3.2 h and 3.9 h, respectively. Pharmacodynamic activity in rats is exposure-dependent: a 60 mpk dose causes complete inhibition of palmitate synthesis 12h after administration while a single 30 mpk oral dose causes >50 % inhibition at 12h. Palmitate synthesis remains suppressed by ~60% at 24 hours following a 60 mpk dose, consistent with a once-daily oral dosing regimen. The results of this current work demonstrate that 3-V Bioscience's FASN inhibitor can inhibit *de novo* fatty acid synthesis *in vivo* and has pharmaceutical properties necessary for clinical development.

In Vitro Activity Against Human, Rat, and Dog FASN




Species	Cell Line	Biochemical (μM)*	Palmitate (μM)†
Human	HeLa Ohio	0.049	0.025
Human	Huh-7	0.049	0.049
Dog	MDCK NBL-2	Not Tested	0.27
Rat	NMU	0.11	0.090


* Biochemical assay: measures the activity of human (crude extract from SKBr3 cells) or rat (purified from rat liver) FASN by measuring the release of coenzyme A with the dye CPM
† Palmitate assay: To measure *de novo* synthesis of palmitate by FASN, a stable labeled substrate (¹³C₂ acetate) was added to cells and ¹³C₂ labeled palmitate was measured by LC-MS.

Oral Pharmacokinetics in Rats and Dogs

Dogs and rats display similar apparent half-lives after oral doses of 10 mg/kg, however exposures are 10 X higher in dogs





Dose and Exposure Relationships to Inhibition of *de novo* Palmitate Synthesis In Vivo



Rats were dosed with vehicle or doses of 3-V FASN inhibitor between 10 and 90mpk. 2 h prior to sacrifice, rats were injected with ¹³C₂ acetate tracer. ¹³C₂-palmitate was measured by LC-MS.

Sustained Inhibition of Palmitate Synthesis After a Single Dose



Rats were dosed with vehicle or doses of 30 or 60 mg/kg 3-V FASN inhibitor. 2 h prior to sacrifice, either 10 or 22 hours post dose, rats were injected with ¹³C₂ acetate. ¹³C₂-palmitate was measured by LC-MS

Conclusions

- 3-V's small molecule FASN inhibitor is a potent inhibitor of human fatty acid synthase
- A single oral dose can inhibit *de novo* palmitate synthesis up to 24 hours *in vivo*
- Inhibition is reversible *in vivo*
- Reduction of *de novo* palmitate synthesis correlates with liver concentration of the drug
- The drug's profile meets the criteria to advance into Phase 1 clinical studies in 2013

Disclosure: All authors are current or former employees of 3-V Biosciences, Inc.